ANF Volume Alert - ANF 28.65 Abercrombie & Fitch Company

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 2:18 PM

ANF Volume Alert - ANF 28.65 Abercrombie & Fitch Company $ANF Hit a high of 29.28 Currently 11:15 Last price 28.65 -0.85 -2.88% With a day low of 28.46 and a current volume of 2,019,334.

ANF Abercrombie & Fitch Company Recent Headline News

Abercrombie & Fitch (ANF) Breaks Through Support at $28.65
Comtex SmarTrend(R) - 1 hr 46 mins ago
Shares of Abercrombie & Fitch (NYSE:ANF) opened today below their pivot of $30.10 and have already reached the first level of support at $28.65. Investors may be interested in a cross of the next downside pivot targets of $27.80 and $25.50.
ANF: 28.56 (-0.94)

Confidence in Abercombie & Fitch continues to erode
Seeking Alpha - at Seeking Alpha - 2 hrs 35 mins ago

ANF: 28.56 (-0.94)

Abercrombie & Fitch Posts Weak Q3 Sales, Guides Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 9:45AM CST
Shares of Abercrombie & Fitch (ANF) have plunged 16.6% since the company announced its sales results and earnings outlook for the third quarter of 2014.
LB: 76.06 (+0.45), ANF: 28.56 (-0.94), CTRN: 22.21 (+0.41), ARO: 2.91 (-0.24)

One Reason Abercrombie & Fitch (ANF) Stock Is Falling Today
at The Street - Mon Nov 10, 9:23AM CST
Shares of Abercrombie & Fitch (ANF) are down after the company was downgraded to 'perform' from 'outperform' at Oppenheimer.
ANF: 28.56 (-0.94)

Downgrade Alert for Abercrombie & Fitch (ANF)
Comtex SmarTrend(R) - Mon Nov 10, 7:55AM CST
Abercrombie & Fitch (NYSE:ANF) was downgraded from Buy to Neutral at Janney Montgomery today. The stock closed yesterday at $29.50 on volume of 14.4 million shares, above average daily volume of 2.4 million. Abercrombie & Fitch Co. is a specialty retailer that operates stores selling casual apparel, such as knit shirts, graphic t-shirts, jeans, woven shirts and personal care and other accessories for men, women and kids. The Company operates stores in the United States and Canada as well as retails its products over the Internet.
ANF: 28.56 (-0.94)

Earnings Forecast Buzz for Alibaba, Genworth Financial, Gilead Sciences, Zynga, Abercrombie & Fitch, and Plug Power
PR Newswire - Mon Nov 10, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Genworth Financial (NYSE:GNW), Gilead Sciences (NASDAQ:GILD), Zynga (NASDAQ:ZNGA), Abercrombie & Fitch (NYSE:ANF), and Plug Power (NASDAQ

LUG).
GILD: 107.37 (+0.92), PLUG: 5.25 (-0.05), ANF: 28.56 (-0.94), ZNGA: 2.44 (+0.01), GNW: 8.28 (-0.13), BABA: 117.42 (+2.86)

Abercrombie & Fitch reports business update for Q3 2014
M2 - Mon Nov 10, 4:28AM CST
Abercrombie & Fitch (NYSE: ANF), a specialty retailer of casual apparel for men, women and kids, on Friday provided a business update for Q3 2014, ended 1 November 2014, and reported that net sales decreased 12% to USD911.4m, as compared to net sales of USD1.033bn in Q3 of the prior year.
ANF: 28.57 (-0.93)

Why We Don't Care For American Eagle
Main Street Wins - at Seeking Alpha - Mon Nov 10, 3:39AM CST

ANF: 28.57 (-0.93), AEO: 12.37 (-0.57)

Pity The Hedge Fund Manager
George Acs - at Seeking Alpha - Sat Nov 08, 12:13PM CST

CY: 10.15 (+0.07), EBAY: 53.79 (+0.28), MAT: 31.49 (-0.18), ANF: 28.57 (-0.93), IP: 53.45 (+0.58), MOS: 44.11 (+0.08), SBGI: 26.74 (-0.30), TWTR: 39.84 (-0.47), INTC: 33.25 (-0.33)

'Fast Money' Recap: When Is the Best Time to Buy Twitter Stock?
at The Street - Sat Nov 08, 4:00AM CST
The trading panel discussed whether it would help or hurt Twitter if its CEO steps down and whether Coca-Cola has any fizz left in it.
KO: 42.28 (-0.04), YHOO: 49.22 (+0.67), MNST: 107.06 (-1.33), ANF: 28.57 (-0.93), SLXP: 93.39 (+1.92), FFIV: 126.84 (+0.18), AKS: 6.58 (-0.04), TWTR: 39.84 (-0.47), GDX: 17.56 (-1.08), FXF: 100.85 (-0.25)

Abercrombie warns on Q3
at Investor's Business Daily - Fri Nov 07, 5:36PM CST
The young men's and women's apparel retailer is still having trouble getting teens to buy its clothing. Abercrombie & Fitch (ANF), which faces tough competition from rivals such as Forever 21 and H&M, said in a Q3 update that net sales fell 12% to...
ANF: 28.57 (-0.93)

NYSE stocks posting largest percentage decreases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at the close of trading:
PNK: 22.33 (-0.52), CZZ: 9.36 (-0.06), PBH: 31.49 (-1.30), TCAP: 22.86 (-0.61), MED: 29.76 (-0.01), AMBR: 11.17 (-0.23), ANF: 28.57 (-0.93), NSM: 27.80 (-2.03), NKA: 5.08 (-0.33), GNW: 8.28 (-0.13), HGR: 20.85 (+0.97), KOP: 31.63 (-0.84)

Abercrombie & Fitch Set to Possibly Rebound After Yesterday's Selloff of 16.62%
Comtex SmarTrend(R) - Fri Nov 07, 3:45PM CST
Abercrombie & Fitch (NYSE:ANF) traded in a range yesterday that spanned from a low of $29.25 to a high of $31.55. Yesterday, the shares fell 16.6%, which took the trading range below the 3-day low of $31.90 on volume of 14.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ANF: 28.57 (-0.93)

SmarTrend Watching for Potential Rebound in Shares of Abercrombie & Fitch After 16.62% Loss
Comtex SmarTrend(R) - Fri Nov 07, 3:44PM CST
Abercrombie & Fitch (NYSE:ANF) traded in a range yesterday that spanned from a low of $29.25 to a high of $31.55. Yesterday, the shares fell 16.6%, which took the trading range below the 3-day low of $31.90 on volume of 14.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ANF: 28.57 (-0.93)

Wunderlich throws in the towel on teens, downgrades A&F to Hold
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 2:22PM CST

ANF: 28.57 (-0.93)

Abercrombie & Fitch reports sharp drop in sales
AP - Fri Nov 07, 9:43AM CST
NEW YORK (AP) — Abercrombie & Fitch is still having trouble getting teens to buy its clothing.
ANF: 28.57 (-0.93)

Abercrombie & Fitch (ANF) Stock Plummeting Today After Earnings Update
at The Street - Fri Nov 07, 9:11AM CST
Abercrombie & Fitch (ANF) stock is plunging after the company issued a guidance warning for the 2014 third quarter.
ANF: 28.57 (-0.93)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST

BEBE: 2.38 (-0.02), ANET: 79.77 (+1.94), TKMR: 16.49 (-0.26), ORBC: 5.94 (+0.14), MDRX: 11.34 (-0.20), RMTI: 10.59 (+0.04), CTIC: 2.10 (-0.03), SHLD: 39.63 (-3.18), UBNT: 29.44 (+0.66), RIG: 29.42 (-0.29), KGC: 2.34 (-0.16), APT: 3.27 (+0.01), ANF: 28.57 (-0.93), MITK: 3.14 (+0.18), ZNGA: 2.44 (+0.01), CNET: 2.12 (+0.01), KING: 13.73 (+0.01), NETE: 1.44 (+0.02), SLXP: 93.39 (+1.92), RPRX: 9.27 (-0.85), NADL: 5.12 (-0.32), PGNX: 5.72 (+0.35), AVNR: 13.20 (+0.18), FSLR: 51.82 (+1.53), DVA: 74.50 (+0.01), NDLS: 24.66 (-0.16), ICPT: 177.00 (+4.41), AGIO: 79.98 (+7.92), PLNR: 7.47 (+1.07)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Love Business Group Helps SMEs Navigate Broadband Choices

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

D-Wave Investors Must Decide by Dec 15 Class Suit

Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...

Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...